image description
image description

Kaloba Tablets – SPC

Summary of Product Characteristics

1 Name of the medicinal product

  • Kaloba Pelargonium Cough & Cold Relief tablets
  • Higher Nature Pelargonium Cold Relief film-coated tablets
  • Healthspan Pelargonium Cold Relief tablets

2 Qualitative and quantitative composition

1 film-coated tablet contains 20 mg of extract (as dry extract) from the roots of Pelargonium sidoides DC (1 : 8 – 10) (EPs® 7630)  Extraction solvent 11% ethanol (w/w).


One film-coated tablet contains 20 mg lactose monohydrate.

For a full list of excipients, see section 6.1.

3 Pharmaceutical form

Film-coated tablet

Round, reddish-brown, smooth surface film coating without ruptures.

4 Clinical particulars

4.1 Therapeutic indications

Traditional herbal medicinal product used to relieve the symptoms of upper respiratory tract infections including the common cold, such as sore throat, cough and blocked or runny nose, based on traditional use only.

4.2 Posology and method of administration

Adults and adolescents over 12 years of age:
Take 1 tablet three times daily (morning, midday, evening).

Tablets should be swallowed whole with a little water. The tablets should not be chewed.

The use in children under 12 years of age is not recommended (see section 4.4 `Special warnings and precautions for use`).

Duration of use:

After relief of symptoms, continuation of treatment is recommended for a further 2 – 3 days in order to prevent a relapse. However, treatment duration should not exceed 2 weeks.

If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

4.3 Contraindications

Kaloba is not to be used in the following cases:

  • hypersensitivity to the active substance or to any of the excipients,
  • increased tendency to bleeding,
  • patients using coagulation-inhibiting drugs,
  • severe hepatic and renal diseases, due to lack of adequate data.

4.4 Special warnings and special precautions for use

In the patient information leaflet, the patient is advised to consult a doctor immediately if his or her condition does not improve within one week, in case of fever lasting for several days or in case of shortness of breath or blood in the sputum.

One film-coated tablet contains 20 mg lactose monohydrate.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

On theoretical grounds Kaloba should not be used where there is a likelihood of increased tendency to bleeding or use of coagulation-inhibiting drugs.

Kaloba should not be used in case of severe hepatic and renal diseases, due to lack of adequate data.

This formulation is not suitable for children under 12 years of age.

4.5 Interaction with other medicinal products and other forms of interaction

Drug interactions have not been reported to date.

However, due to the potential effect of Kaloba on coagulation parameters, this product may enhance the effect of coagulation-inhibiting drugs such as warfarin and should not be taken concomitantly with these drugs. (see section 4.3).

4.6 Pregnancy and lactation

Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7 Effects on ability to drive and use machine

No studies on the effect on the ability to drive and use machines have been performed.

4.8 Undesirable effects

The evaluation of adverse reactions is based on the following information on frequency:

Very common:
more than 1 out of 10 treated persons

more than 1 out of 100 treated persons

more than 1 out of 1000 treated persons

more than 1 out of 10 000 treated persons

Very rare:
1 or less out of 10 000 treated persons including single cases

Gastro-intestinal complaints such as stomach pain, heartburn, nausea or diarrhoea may occur uncommonly (≥ 1/1,000 to < 1/100) during treatment with Kaloba.

In rare cases (≥1/10,000 to ≤ 1/1,000), mild bleeding from the gums or nose may occur. Furthermore, hypersensitivity reactions (e.g. exanthema, urticaria, pruritus of skin and mucous membranes) have been described in rare cases. Such reactions may occur after the first intake of the product.

In very rare cases (≤ 1/10,000), serious hypersensitivity reactions with swelling of the face, dyspnoea and drop in blood pressure may occur.

In single cases, signs indicating disturbances of liver function have been reported after intake of Kaloba; the causal relationship between this effect and the use of the product has not been demonstrated.

If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

4.9 Overdose

The effects of overdose are unknown.

Although there are no data on cases of overdose, overdose is likely to increase side-effects. Thus, treatment should be symptomatic and as clinically indicated.

5 Pharmacological properties

5.1 Pharmacodynamic properties

Not required.

5.2 Pharmacokinetic properties

Not required.

5.3 Preclinical safety data

Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6 Pharmaceutical particulars

6.1 List of excipients


  • Maltodextrin

Tablet core:

  • Maltodextrin
  • Microcrystalline cellulose
  • Lactose monohydrate
  • Croscarmellose sodium,
  • Precipitated silica
  • Magnesium stearate


  • Hypromellose 5 mPas
  • Macrogol 1500
  • Iron oxide yellow E172
  • Iron oxide red E172
  • Titanium dioxide E171
  • Talc
  • Simeticone
  • Methylcellulose
  • Sorbic acid.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

4 years.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Original packages containing 16, 21 or 30 film coated tablets (Kaloba Pelargonium Cough & Cold Relief tablets) or 30 (Healthspan Pelargonium Cold Relief tablets) or 21 (Higher Nature Pelargonium Cold Relief film-coated tablets).

The tablets are packed in PVC/ PVDC aluminium blisters and inserted into a carton together with the package leaflet.

6.6 Special precautions for disposal and other handling

No special requirements.

7 Marketing authorisation holder

Dr. Willmar Schwabe GmbH & Co. KG
Willmar-Schwabe-Str. 4
D-76227 Karlsruhe

Distributed in the UK by:

Schwabe Pharma (UK) Ltd
Alexander House
Mere Park
Dedmere Road

8 Marketing authorisation number(s)

THR 05332/0005

9. Date of first authorisation/renewal of the authorisation

31st March 2009

10 Date of revision of the text

12th July 2013

A Guide to Herbal Medicines

Download our comprehensive guide to popular traditional herbal medicines and food supplements for minor ailments.

image description

Visit Vitamin Expert

Everything you need to know about herbal medicines and food supplements. image description

Nature's Way

Visit Nature’s Way - our sister-site for vitamins, minerals and food supplements. image description

Take a FREE health check

Try one of our quick health checkers.

image description

Email Sign Up

Receive email updates on product offers and natural health news.

image description